Potential Immunological Treatments in COVID-19 Patients
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seemed in Wuhan, China in December 2019. SARS-CoV-2 infection in human was named as coronavirus disease 2019 (COVID-19). It has now infected more than 69 million people worldwide, becoming an epidemic responsible for more than 1,5 million...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Duzce University
2021-04-01
|
| Series: | Düzce Tıp Fakültesi Dergisi |
| Subjects: | |
| Online Access: | https://dergipark.org.tr/tr/pub/dtfd/issue/60168/856165 |
| _version_ | 1797421326780071936 |
|---|---|
| author | Muhammet Mesut Nezir Engin Öner Özdemir |
| author_facet | Muhammet Mesut Nezir Engin Öner Özdemir |
| author_sort | Muhammet Mesut Nezir Engin |
| collection | DOAJ |
| description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seemed in Wuhan, China in December 2019. SARS-CoV-2 infection in human was named as coronavirus disease 2019 (COVID-19). It has now infected more than 69 million people worldwide, becoming an epidemic responsible for more than 1,5 million deaths until 10th of December 2020. The epidemic still continues. This epidemic is the third epidemic caused by coronaviruses in the 21st century and may be the most important infectious disease representing a major public health threat to the whole world. Treatments against COVID-19 are constantly updated in the literature, based on evidence. Unfortunately, there is no definitive cure for COVID-19, and a number of drugs for use in severe cases of COVID-19 are now being studied in a number of nonrandomized or randomized trials. These include chloroquine, steroids, anti-inflammatory, and antiviral agents. Immunological treatments such as convalescent plasma, intravenous immunoglobulin, monoclonal antibodies (tocilizumab, eculizumab, itolizumab etc.), and anakinra treatments are tried in COVID-19 disease. Results from some trials look promising. Quite a few reports have also stood published so far on the use of immunological treatments for COVID-19 cases. In this review, we will discuss the key immunological treatments, mostly mentioned in the current literature, used in COVID-19 patients in detail. |
| first_indexed | 2024-03-09T07:14:20Z |
| format | Article |
| id | doaj.art-6f7f6d9e2a4f4ffc9768fadc03ab9e68 |
| institution | Directory Open Access Journal |
| issn | 1307-671X |
| language | English |
| last_indexed | 2024-03-09T07:14:20Z |
| publishDate | 2021-04-01 |
| publisher | Duzce University |
| record_format | Article |
| series | Düzce Tıp Fakültesi Dergisi |
| spelling | doaj.art-6f7f6d9e2a4f4ffc9768fadc03ab9e682023-12-03T08:44:53ZengDuzce UniversityDüzce Tıp Fakültesi Dergisi1307-671X2021-04-012311910.18678/dtfd.85616597Potential Immunological Treatments in COVID-19 PatientsMuhammet Mesut Nezir Engin0Öner Özdemir1SAKARYA SAĞLIK BAKANLIĞI SAKARYA ÜNİVERSİTESİ EĞİTİM VE ARAŞTIRMA HASTANESİSAKARYA UNIVERSITY, FACULTY OF MEDICINESevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seemed in Wuhan, China in December 2019. SARS-CoV-2 infection in human was named as coronavirus disease 2019 (COVID-19). It has now infected more than 69 million people worldwide, becoming an epidemic responsible for more than 1,5 million deaths until 10th of December 2020. The epidemic still continues. This epidemic is the third epidemic caused by coronaviruses in the 21st century and may be the most important infectious disease representing a major public health threat to the whole world. Treatments against COVID-19 are constantly updated in the literature, based on evidence. Unfortunately, there is no definitive cure for COVID-19, and a number of drugs for use in severe cases of COVID-19 are now being studied in a number of nonrandomized or randomized trials. These include chloroquine, steroids, anti-inflammatory, and antiviral agents. Immunological treatments such as convalescent plasma, intravenous immunoglobulin, monoclonal antibodies (tocilizumab, eculizumab, itolizumab etc.), and anakinra treatments are tried in COVID-19 disease. Results from some trials look promising. Quite a few reports have also stood published so far on the use of immunological treatments for COVID-19 cases. In this review, we will discuss the key immunological treatments, mostly mentioned in the current literature, used in COVID-19 patients in detail.https://dergipark.org.tr/tr/pub/dtfd/issue/60168/856165anakinrabamlanivimabcovid-19konvalesan plazmaeculizumabintravenöz immünoglobulinitolizumabmonoklonal antikorlarsarilumabsiltuximabtocilizumabsvilobelimabanakinrabamlanivimabcovid-19convalescent plasmaeculizumabintravenous immunoglobulinitolizumabmonoclonal antibodiessarilumabsiltuximabtocilizumabsvilobelimab |
| spellingShingle | Muhammet Mesut Nezir Engin Öner Özdemir Potential Immunological Treatments in COVID-19 Patients Düzce Tıp Fakültesi Dergisi anakinra bamlanivimab covid-19 konvalesan plazma eculizumab intravenöz immünoglobulin itolizumab monoklonal antikorlar sarilumab siltuximab tocilizumab svilobelimab anakinra bamlanivimab covid-19 convalescent plasma eculizumab intravenous immunoglobulin itolizumab monoclonal antibodies sarilumab siltuximab tocilizumab svilobelimab |
| title | Potential Immunological Treatments in COVID-19 Patients |
| title_full | Potential Immunological Treatments in COVID-19 Patients |
| title_fullStr | Potential Immunological Treatments in COVID-19 Patients |
| title_full_unstemmed | Potential Immunological Treatments in COVID-19 Patients |
| title_short | Potential Immunological Treatments in COVID-19 Patients |
| title_sort | potential immunological treatments in covid 19 patients |
| topic | anakinra bamlanivimab covid-19 konvalesan plazma eculizumab intravenöz immünoglobulin itolizumab monoklonal antikorlar sarilumab siltuximab tocilizumab svilobelimab anakinra bamlanivimab covid-19 convalescent plasma eculizumab intravenous immunoglobulin itolizumab monoclonal antibodies sarilumab siltuximab tocilizumab svilobelimab |
| url | https://dergipark.org.tr/tr/pub/dtfd/issue/60168/856165 |
| work_keys_str_mv | AT muhammetmesutnezirengin potentialimmunologicaltreatmentsincovid19patients AT onerozdemir potentialimmunologicaltreatmentsincovid19patients |